England Study Confirms 100 Myocarditis Deaths After COVID Shots

    0
    366

    by Suzanne Burdick, Ph.D., Childrens Health Defense:

    In the largest study to date on myocarditis deaths related to COVID-19 vaccination, researchers found that 100 people in England died of myocarditis soon after receiving a COVID-19 vaccine.

    In the largest study to date on myocarditis deaths related to COVID-19 vaccination, researchers found that 100 people in England died of myocarditis soon after receiving a COVID-19 vaccine.

    TRUTH LIVES on at https://sgtreport.tv/

    The study, published Aug. 22 in the American Heart Association’s journal, Circulation, found more than half (51) of the deaths occurred within 1 to 28 days after receiving a dose of the AstraZeneca vaccine and just under half (49) of the deaths occurred within 1 to 28 days after a dose of the Pfizer-BioNTech vaccine.

    The AstraZeneca vaccine, not authorized for use in the U.S., uses an adenovirus technology similar to that used by Johnson & Johnson’s (J&J), or Janssen) COVID-19 vaccine, which is authorized for emergency use in the U.S.

    Prior research has underscored the risk of fatal myocarditis associated with the mRNA technology used in the Pfizer and Moderna COVID-19 vaccines. This study showed the technology used in AstraZeneca’s vaccine poses a similar risk.

    Dr. Peter McCullough, an internist and cardiologist in Dallas, Texas, in a Sept. 15 tweet highlighted the importance of the new study.

    “This study confirms the risk of myocarditis extends to both mRNA vaccines and the adenovirus vaccines,” McCullough told The Defender.

    The technology used in AstraZeneca and J&J viral vector vaccines, as The Defender previously reported, causes cells to produce the spike protein, but in a different way than the mRNA shots.

    The technology uses a familiar virus — adenovirus — which is a common cause of respiratory infections. The DNA in the adenovirus is modified so that when it enters the host cell, it causes the cell’s own machinery to produce the spike protein.

    The adenovirus also is modified so it cannot replicate itself, which is why it is called a replication-defective recombinant adenoviral vector vaccine.

    How the study was conducted

    The team of 14 researchers — led by Martina Patone, Ph.D., a data scientist and medical statistician at the University of Oxford — analyzed data for people ages 13 and older who were vaccinated against COVID-19 in England between Dec. 1, 2020, and Dec. 15, 2021.

    The authors evaluated the association between vaccination and myocarditis for different ages and sex groups by tracking hospital admissions and deaths from myocarditis by age and gender and in relation to how many doses of a vaccine the person received.

    In England, the three COVID-19 vaccines given to people at that time were the Pfizer, Moderna and AstraZeneca vaccines.

    Roughly 20 million people got the AstraZeneca vaccine, 20 million got the Pfizer vaccine, and just over 1 million got the Moderna vaccine.

    Over the period of the study, 345 patients were admitted to the hospital for myocarditis within 1 to 28 days of receiving a COVID-19 vaccine, the authors said.

    Among those admitted to the hospital for myocarditis who recently received the AstraZeneca vaccine, the researchers counted 40 deaths due to myocarditis within 1 to 28 days after a first dose and 11 deaths due to myocarditis within 1 to 28 days after a second dose.

    For those who received the Pfizer vaccine, 22 individuals died of myocarditis within 1 to 28 days of receiving their first dose, 14 died of myocarditis within 1 to 28 days of receiving a second dose and 13 died of myocarditis within 1 to 28 days of receiving a third dose.

    The researchers reported no cases of fatal myocarditis among those who recently received the Moderna vaccine.

    However, when they used statistical methods to estimate an “incidence rate ratio” to describe how often people reported myocarditis following vaccination, they found an increased risk of developing myocarditis following all three vaccine types — especially after a second dose of the Moderna vaccine.

    Following a second dose of the Moderna vaccine, they said, the increased risk ratio for developing myocarditis was 11.76 (95% CI, 7.25-19.08).

    Men under age 40, as a group, showed a heightened increased risk of myocarditis following all three vaccine types.

    After the first dose of the Pfizer vaccine, the increased risk ratio for men under 40 years old was 1.85 (95% CI, 1.30-2.62). It increased to 1.93 (95% CI, 1.51-2.45) after the second dose and was 1.89 (95% CI,1.34-2.67) after the third dose.

    Similarly, the researchers reported a high increased risk ratio of 3.06 (95% CI, 1.33-7.03) after the first dose of the Modern vaccine for men under 40. The risk rose to 16.83 (95% CI, 9.11-31.1) after a second dose. After a third dose, the increased risk ratio was 3.57 (95% CI, 1.48-8.64).

    Among men under 40 who received the AstraZeneca vaccine, the increased risk ratio for myocarditis after the first dose was 1.33 (95% CI, 1.03-1.72) and after the second dose was 1.26 (95% CI, 0.96-1.65).

    The team said their findings will enable “an informed discussion of the risk of vaccine associated myocarditis.”

    While this study is important because it presents the largest published series of fatal myocarditis cases and linked them to both mRNA and adenovirus COVID-19 vaccines, McCullough said another of its conclusions is “misleading.”

    Read More @ ChildrensHealthDefense.org